Tesamorelin Ipamorelin Blend Dosage Calculator
An unapproved fixed-ratio blend that should not be confused with FDA-approved tesamorelin products. No study has tested the combination.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
The blend is not approved and is not EGRIFTA
Tesamorelin is FDA-approved only in the specific EGRIFTA WR and EGRIFTA SV formulations for HIV-associated lipodystrophy. Ipamorelin is not FDA-approved, and the FDA's advisory committee voted against adding it to the 503A bulks list in October 2024. A vial combining the two has no approval, label or standardized composition.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times. Tesamorelin is a GHRH analogue and ipamorelin a growth-hormone secretagogue; both fall within WADA class S2.
Key facts
- Half-life
- Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
- Also sold as
- Tesamorelin ipamorelin blend
Published doses
How good is the evidence?
No published human study has administered tesamorelin and ipamorelin together. The approved tesamorelin label and the single-dose ipamorelin pharmacology study concern different products, routes and questions; neither validates the blend.
Why an EGRIFTA dose does not become a blend dose
The EGRIFTA labels describe two complete manufactured products. WR contains 11.6 mg tesamorelin, uses its supplied bacteriostatic water and delivers a labelled 1.28 mg daily dose; SV contains 2 mg, uses sterile water and delivers 1.4 mg. The labels explicitly say even those two tesamorelin products are not substitutable.
A vendor vial with ipamorelin added is further removed: its formulation, concentration and fixed ratio are different, and no label describes it. Copying an EGRIFTA tesamorelin number into the blend automatically produces some amount of ipamorelin that no study chose or evaluated.
One draw forces both components
In the illustrative 10 mg plus 5 mg vial, every draw contains twice as much tesamorelin as ipamorelin by mass. If a draw contains 1 mg tesamorelin, it necessarily contains 0.5 mg ipamorelin. Adding water changes the number of syringe units but never that 2:1 relationship.
That arithmetic is exact if the label is accurate. It is not evidence that either amount is appropriate. The calculator reports the consequence of a target you enter; it does not supply the target.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- FDA labelFDA / DailyMedEGRIFTA WR (tesamorelin) for injection — FDA prescribing information and Instructions for Use
- FDA labelFDA / DailyMedEGRIFTA SV (tesamorelin) for injection — FDA prescribing information
- RegulatorFDA· 2024-10October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- Published studyPharmaceutical Research· 1999Gobburu JVS et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy men